Christopher A. Chamberlain

827 total citations
22 papers, 571 citations indexed

About

Christopher A. Chamberlain is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Christopher A. Chamberlain has authored 22 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Christopher A. Chamberlain's work include Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (12 papers) and CAR-T cell therapy research (11 papers). Christopher A. Chamberlain is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (12 papers) and CAR-T cell therapy research (11 papers). Christopher A. Chamberlain collaborates with scholars based in Denmark, Hungary and Sweden. Christopher A. Chamberlain's co-authors include Marco Donia, Inge Marie Svane, Özcan Met, Kasper Mølgaard, Arianna Draghi, Eric Bennett, Troels Holz Borch, Anders Kverneland, Andrew J.S. Furness and Morten Nielsen and has published in prestigious journals such as Nucleic Acids Research, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Christopher A. Chamberlain

21 papers receiving 563 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher A. Chamberlain Denmark	12	415	300	166	63	38	22	571
Gina Scurti United States	11	281 0.7×	323 1.1×	182 1.1×	51 0.8×	34 0.9×	23	539
Maxime Dhainaut United States	7	335 0.8×	436 1.5×	240 1.4×	43 0.7×	56 1.5×	12	707
Alexander H. Pearlman United States	5	214 0.5×	138 0.5×	223 1.3×	46 0.7×	34 0.9×	6	445
Suzan Lazo United States	5	487 1.2×	526 1.8×	375 2.3×	36 0.6×	42 1.1×	6	903
Houssem Benlalam France	14	294 0.7×	364 1.2×	243 1.5×	32 0.5×	26 0.7×	20	600
Emily Cheney United States	4	385 0.9×	275 0.9×	252 1.5×	26 0.4×	24 0.6×	5	573
Christie Fanton United States	11	288 0.7×	267 0.9×	198 1.2×	34 0.5×	21 0.6×	26	587
J H S Diepstra Netherlands	7	257 0.6×	412 1.4×	327 2.0×	39 0.6×	36 0.9×	8	664
Ying Gong China	8	266 0.6×	280 0.9×	130 0.8×	44 0.7×	42 1.1×	25	443
Margaret D. Zimmer United States	4	446 1.1×	416 1.4×	480 2.9×	70 1.1×	32 0.8×	4	865

Countries citing papers authored by Christopher A. Chamberlain

Since Specialization

Citations

This map shows the geographic impact of Christopher A. Chamberlain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher A. Chamberlain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher A. Chamberlain more than expected).

Fields of papers citing papers by Christopher A. Chamberlain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher A. Chamberlain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher A. Chamberlain. The network helps show where Christopher A. Chamberlain may publish in the future.

Co-authorship network of co-authors of Christopher A. Chamberlain

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher A. Chamberlain. A scholar is included among the top collaborators of Christopher A. Chamberlain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher A. Chamberlain. Christopher A. Chamberlain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seremet, Tina, et al.. (2025). ProS1-MerTK signaling in CD4 T cells: implications for TIL expansion and functionality. OncoImmunology. 14(1). 2532662–2532662. 1 indexed citations

Petersen, David L., Marie Just Mikkelsen, Özcan Met, et al.. (2024). Analyzing functional heterogeneity of effector cells for enhanced adoptive cell therapy applications. Immuno-Oncology Technology. 24. 100738–100738.

Draghi, Arianna, Christopher A. Chamberlain, Mads Hald Andersen, et al.. (2023). Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma. Clinical Cancer Research. 29(19). 3937–3947. 11 indexed citations

Nielsen, Morten, Zsófia Sztupinszki, Arianna Draghi, et al.. (2022). Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy. Cancer Immunology Research. 10(10). 1254–1262. 9 indexed citations

Chamberlain, Christopher A., Eric Bennett, Anders Kverneland, et al.. (2022). Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Molecular Therapy — Oncolytics. 24. 417–428. 50 indexed citations

Chen, Inna M., Marco Donia, Christopher A. Chamberlain, et al.. (2022). Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). European Journal of Cancer. 180. 125–133. 23 indexed citations

Chen, Inna M., Marco Donia, Christopher A. Chamberlain, et al.. (2022). Phase 2 Study of Ipilimumab, Nivolumab, and Tocilizumab Combined with Stereotactic Body Radiotherapy in Patients with Refractory Pancreatic Cancer (TRIPLE-R). SSRN Electronic Journal. 4 indexed citations

Kverneland, Anders, Christopher A. Chamberlain, Troels Holz Borch, et al.. (2021). Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. Journal for ImmunoTherapy of Cancer. 9(10). e003499–e003499. 45 indexed citations

Draghi, Arianna, Christopher A. Chamberlain, Shawez Khan, et al.. (2021). Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens. Frontiers in Immunology. 12. 705422–705422. 14 indexed citations

10.

Lauss, Martin, Katja Harbst, Christopher A. Chamberlain, et al.. (2021). Transcriptomic signatures of tumors undergoing T cell attack. Cancer Immunology Immunotherapy. 71(3). 553–563. 6 indexed citations

11.

Chamberlain, Christopher A., et al.. (2021). ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors. SHILAP Revista de lepidopterología. 1(3). 194–211. 13 indexed citations

12.

Kverneland, Anders, Troels Holz Borch, Christopher A. Chamberlain, et al.. (2020). 1022MO Clinical potential of adoptive cell therapy with tumour infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma patients. Annals of Oncology. 31. S706–S706. 1 indexed citations

13.

Westergaard, Marie Christine Wulff, et al.. (2020). The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro. Cancer Immunology Immunotherapy. 70(6). 1771–1776. 11 indexed citations

14.

Draghi, Arianna, Krisztián Papp, Troels Holz Borch, et al.. (2020). Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma. Cancers. 12(11). 3344–3344. 24 indexed citations

15.

Bennett, Eric, Bent Larsen Petersen, Ida Elisabeth Johansen, et al.. (2020). INDEL detection, the ‘Achilles heel’ of precise genome editing: a survey of methods for accurate profiling of gene editing induced indels. Nucleic Acids Research. 48(21). 11958–11981. 63 indexed citations

16.

Met, Özcan, Kasper Mølgaard, Christopher A. Chamberlain, Marco Donia, & Inge Marie Svane. (2018). Principles of adoptive T cell therapy in cancer. Seminars in Immunopathology. 41(1). 49–58. 162 indexed citations

17.

Draghi, Arianna, Christopher A. Chamberlain, Andrew J.S. Furness, & Marco Donia. (2018). Acquired resistance to cancer immunotherapy. Seminars in Immunopathology. 41(1). 31–40. 35 indexed citations

18.

Andersen, Rikke, Troels Holz Borch, Arianna Draghi, et al.. (2018). T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Annals of Oncology. 29(7). 1575–1581. 51 indexed citations

19.

Draghi, Arianna, et al.. (2018). Differential effects of corticosteroids and anti‐TNF on tumor‐specific immune responses: implications for the management of irAEs. International Journal of Cancer. 145(5). 1408–1413. 37 indexed citations

20.

Stone, Shane R., et al.. (2018). β-Lactamase Tools for Establishing Cell Internalization and Cytosolic Delivery of Cell Penetrating Peptides. Biomolecules. 8(3). 51–51. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact